The respectively. Metabolic profiling revealed that CP-544439 was primarily metabolized via glucuronidation, reduction, and hydrolysis. Glucuronidation was the primary route of metabolism in dogs, whereas reduction of the hydroxamate moiety was the major pathway in rats. Human plasma and urine obtained from a dose escalation study in healthy human volunteers were also analyzed in this study to assess the metabolism of CP-544439 in humans and ensure that selected animal species were exposed to all major metabolites formed in humans. Analysis suggested that CP-544439 was metabolized via all three pathways in humans consistent with rat and dog; however, the glucuronide conjugate M1 was the major circulating and excretory metabolite in humans. Preliminary in vitro phenotyping studies indicated that glucuronide formation is primarily catalyzed by UGT1A1, 1A3, and 1A9.
The matrix metalloproteinases (MMP) are a family of zincdependent enzymes responsible for breaking down extracellular matrix proteins. Overexpression and activation of MMP have been linked to a range of diseases in which the destruction of connective tissue is an important pathological event, such as osteo arthritis (OA) and rheumatoid arthritis, tumor metastasis and angiogenesis, and corneal ulceration (Beckett et al., 1996; Michaelides and Curtin 1999; Rao, 2005) . Collagenase 3 (MMP-13) is one type of MMP that is overexpressed in cartilage tissues of OA patients and is very efficient in the degradation of type II collagen. Thus, MMP-13 has been implicated in the pathology of OA. A selective MMP-13 inhibitor should therefore slow down or prevent cartilage breakdown and improve the quality of life of OA patients by retarding loss of function due to joint deterioration.
4-[4-(4-Fluorophenoxy)-benzenesulfonylamino]tetrahydropyran-4-carboxylic acid hydroxyamide (CP-544439) (Scheme 1) was designed and synthesized as a selective inhibitor of MMP-13 (IC 50 ϭ 0.8 nM) (Reiter et al., 2004) . In vivo studies using a hamster model, in which the cartilage collagen degradation was induced by intra-articular injection of recombinant human MMP-13 (Otterness et al., 2000) , demonstrated that oral administration of CP-544439 inhibits degradation of the cartilage collagen with an ED 50 of 14 mg/kg and efficacious plasma concentrations ranging from 0.5 to 1.0 g/ml.
Preclinical pharmacokinetic studies of CP-544439 in rats and dogs demonstrated that the clearance of CP-544439 was high in rats (53 ml/min/kg) and moderate in dogs (10 ml/min/kg). The volume of distribution ranged from 1.6 to 2.0 l/kg in the two species, and the terminal elimination half-life was 0.9 and 6.5 h in rats and dogs, tration of 50 mg/ml on the day of dose administration. Urine was collected from 0 to 8, 8 to 24, and at 24 h intervals during the study and feces over 24 h intervals, up to 168 h postdose. After the last urine and fecal collection, the cages were washed with 1:1 ethanol/water (v/v) , and the wash was collected. The weight of each fecal sample, cage wash, and the cage debris was determined. All animals were euthanized by CO 2 asphyxiation at the end of the study. For collection of bile, four Sprague-Dawley rats (n ϭ 2/sex) were dosed orally with [
14 C]CP-544439 at a dose of 250 mg/kg for a total radioactive dose of 118 Ci/kg and a specific activity of 0.472 Ci/mg. The dose was formulated in 0.1% methylcellulose/PEG 400 to achieve a concentration of 25 mg/ml. Bile was collected from each animal from 0 to 4, 4 to 8, and 8 to 24 h postdose. Accurate measurements of bile volumes were noted for all time points. After sampling, the bile was stored at Ϫ4°C until assayed. For pharmacokinetic studies, six Sprague-Dawley rats (n ϭ 3/sex) were dosed orally with 250 mg/kg [ 14 C]CP-544439 for a radioactive dose of 202 Ci/kg and a specific activity of 0.81 Ci/mg. The dose was formulated in 1:1 0.5% methylcellulose/PEG 400 to achieve a concentration of 25 mg/ml. Blood was collected predose, 0.5, 1, 2, 4, 7, 25.5, 49.5, 57 , and 72 h postdose. After sampling, whole blood was centrifuged at 14000 rpm for 3 min, and plasma was transferred to Eppendorf (Westbury, NY) snap-capped tubes and stored at Ϫ4°C until assayed.
Dogs. Four noncannulated (two per gender) and two bile-duct cannulated male Beagle dogs were housed individually in stainless steel metabolism cages. [
14 C]CP-544439 was formulated at a target concentration of 20 mg/ml in 0.1% methylcellulose/PEG 400 (1:1) and sonicated until homogenous. A single dose of [
14 C]CP-544439 was administered orally to each dog at a target dose level of 100 mg/kg. The specific activity of the dose was 0.080 Ci/mg. Each dog received a radioactive dose of 8 Ci/kg. Urine was collected from 0 to 8, 8 to 24, and then over 24 h intervals and feces over 24 h intervals, up to 168 h postdose during the study. Blood samples (5 ml) were collected and plasma was obtained prior to dosing and at 0.5, 1, 2, 4, 8, 12, 24, 48, 72 , and 96 h postdose. Bile was collected from the bile-duct cannulated animals up to 8 h after dose. Cage debris was collected after each fecal collection and the cage floors, screens, and pans were rinsed with aqueous ethanol (50%). After the last urine and fecal collection, the cages were washed with aqueous ethanol (50%) and the wash was collected.
Quantitation of Radioactivity. Radioactivity in the urine, bile, and plasma was determined by liquid scintillation counting. Aliquots of plasma, urine, and bile (50 -200 l) were mixed with 15 to 20 ml of Ecolite(ϩ) scintillation cocktail counted in a Wallac Liquid Scintillation Counter model 1409 (PerkinElmer Wallac, Turku, Finland) . The fecal samples and the cage wash were placed in falcon tubes (50 ml) and homogenized in Milli-Q water into a thick slurry using a Brinkmann Polytron lab homogenizer (Brinkmann Instruments, Westbury, NY). The total weight of the homogenate was recorded. Following homogenization, triplicate aliquots (200 l) of each sample were transferred into tared cones and pads, weighed and combusted prior to radiometric analysis, and allowed to dry at ambient temperature for 24 h. All samples were combusted using a Model 307 Sample Oxidizer (PerkinElmer Life and Analytical Sciences). The combustion efficiency was determined prior to the combustion of the samples by using a carbon-14 standard. The resulting 14 CO 2 was trapped in Carbo-Sorb and mixed with Perma-Fluor V scintillation fluid, and the radioactivity was quantified by liquid scintillation counting. The measured radioactivity content in the samples was adjusted using the combustion efficiency values. The samples were analyzed for radioactivity in a Wallac Liquid Scintillation Counter for 2 min. All data obtained on the scintillation counter were automatically corrected for counting efficiency using external standardization technique. The samples obtained before dosing were also counted to obtain background count rate. Samples containing radioactivity (dpm) less than or equal to twice background for the system were assumed to contain 0 dpm in the calculation of the means. The amount of radioactivity in the dose was expressed as 100%, and the percentage of radioactivity in the urine and feces at each sampling time was expressed as the percentage of dose excreted in the respective matrices at the sampling time. The amount of radioactivity in the plasma was expressed as g-equiv. of CP-544439/ml and was calculated using the specific activity of the administered dose.
Quantitation of Unchanged CP-544439. The plasma samples were analyzed for unchanged CP-544439 using HPLC/tandem mass spectrometry. The SCHEME 1. Structure of internal standard (an analog of CP-544439; 20 l of 2.5 g/ml solution in acetonitrile) and 50 l of 0.1% formic acid were added to 100 l of the plasma sample and mixed thoroughly for 5 min. The analytes were extracted from the samples with methyl-tert-butyl ether (1.5 ml). The samples were vortexed for 5 min, and the organic layer was separated by freezing the lower aqueous layer in a dry ice/acetone bath and then decanting the organic layers into fresh 15 ϫ 100 ml conical glass tubes. The organic extract was evaporated to dryness under nitrogen at 50°C. The sample residues were reconstituted in 100 l of 70:30 water/acetonitrile prior to analysis. A 20-l sample was injected on a system that consisted of Agilent quaternary HPLC pump with membrane degasser (Agilent Technologies, Palo Alto, CA) and LEAP autosampler (CTC Analytics; LEAP Technologies Inc., Carrboro, NC) and was attached to a PE-Sciex API 100 mass spectrometer (PerkinElmerSciex Instruments, Boston, MA) equipped with a Turbo Ion Spray Source. The internal standard and CP-544439 were separated chromatographically using a Phenomenex (Torrance, CA) C8 column (2.1 ϫ 150 mm, 5 m) at ambient temperature. The separation was carried out using 10 mM ammonium formate (pH 3) Solvent A, and acetonitrile Solvent B, as mobile phase and at a flow rate of 0.350 l/min. The gradient system used was as follows: 20% solvent A from 0 to 5 min, changed from 20 to 90% solvent A from 5 to 30 min, kept at 90% solvent A from 30 to 34 min, changed from 90 to 20% solvent A over the next 2 min. The column was then allowed to equilibrate at 20% solvent A for the next 5 min before the next sample was injected. Compounds were detected in a negative ion mode, monitoring ions at m/z 409.1 and m/z 367.1 for CP-544439 and the internal standard, respectively. The retention times of CP-544439 and the internal standard were 18.7 and 16.6 min, respectively. Data collection and integration were done on Sciex Software Sample Control (version 1.4) and Mac Quan (version 1.6), respectively. The ratio of peak area responses of drug relative to internal standard was used to construct a standard curve using a linear least square regression with a 1/x 2 weighting. The dynamic range of the assay was 0.01 to 2.0 g/ml. The performance of the assay was monitored by inclusion of quality control samples prepared in rat or dog plasma from a separate weighing.
Determination of Pharmacokinetic Parameters. Pharmacokinetic parameters were determined by noncompartmental methods using WinNonLin version 2.1 (Pharsight, Mountain View, CA). The maximum plasma concentration (C max ) and the time at which this concentration was achieved (T max ) were directly taken from the concentration data. The AUC 0-tlast was calculated from 0 to the last quantifiable time point (T last ) using linear trapezoidal approximation. The plasma terminal elimination rate constant (k el ) was estimated by linear regression analysis of the terminal slope of log plasma concentrationtime curve. The area from T last to infinity (ϱ) was estimated by C tlast /k el , where C tlast represents the estimated plasma concentration at T last , based upon the aforementioned regression analysis. The area under the plasma concentrationtime curve from 0 to ϱ (AUC 0-ϱ ) was estimated as the sum of AUC 0-tlast and AUC T-ϱ . The terminal elimination half-life (t 1/2 ) was estimated as ln2/kel. For estimation of the means and pharmacokinetic parameters, concentrations at the 0 h and those Ͻ0.010 g/ml were assumed to be 0 g/ml.
Extraction, Metabolic Profiling, Identification, and Quantitation of Metabolites in Rat and Dog. Aliquots of plasma, bile, and urine samples at various time points/animal were pooled relative to the excreted volume/mass at each time point, so that Ͼ90% of the radioactivity was accounted for. Pooled samples (0 -72 h, ϳ3 ml) from each animal were centrifuged, and the supernatants were treated with acetonitrile (1:10) followed by a second centrifugation of the mixture. The supernatant was transferred to a glass conical tube and evaporated to dryness under nitrogen at 45°C in a Turbo-Vap (Caliper Life Sciences, Hopkinton, MA). Fecal homogenates at various sampling times were pooled on a weight basis to account for 90% of the radioactivity for each sample. Pooled samples (1 g) were then treated with methanol (15 ml), and the mixture was vortexed and sonicated for approximately 60 min and then centrifuged at 3500 rpm. The supernatants were separated and the process was repeated until most radioactivity (Ͼ90%) was recovered. All supernatants were mixed and evaporated to dryness under nitrogen in a Turbo-Vap at 45°C. All residues were reconstituted in 200 l of acetonitrile/water mixture (1:3) and injected onto the HPLC column without further purification. An aliquot (25 l) was injected onto the LC/MS.
Radiolabeled material in the reconstituted samples was profiled by reverse phase HPLC. The HPLC system consisted of an HP-1100 membrane degasser, HP-1100 autoinjector, HP-1100 binary gradient pump, and a radioactivity on-line detector fitted with a 100-l YtHPSi solid scintillator flow cell (␤-RAM; IN/US, Riviera Beach, FL). Chromatography was carried out on a Phenomenex C8 column (2.1 ϫ 150 mm; 5 m), Zorbax XDB C8, or an Eclipse-XDB fitted with Phenomenex C8 guard column utilizing a binary gradient of a mobile phase consisting of a mixture of 10 mM ammonium formate, pH 3.0 (Solvent A) and acetonitrile (Solvent B). The flow rate was 0.350 ml/min and the separation was achieved at ambient temperature. The gradient was 75% solvent A for the initial 12 min; ramped from 75 to 25% over 35 min in a linear fashion. It was then held at 25% for 1 min, then ramped to 90% in 1 min, held at 90% for 3 min, and changed to 25% in 2 min. The column was then equilibrated at 75% A for the next 5 min before the next injection. The post-column eluate following injection of the extracts was split such that part of the flow was monitored continuously with a ␤-RAM online detector fitted with a 100-l YtHPSi solid scintillator flow cell at a flow rate of 275 l/min. The remaining flow was diverted to the PE SCIEX API 3000 mass spectrometer for characterization of the metabolites. The mass spectrometer was operated in a negative ion mode and fitted with a turbo ion spray interface that was operated at an ion spray voltage (IS) of Ϫ4000 V, orifice voltage (OR) of Ϫ36 V, and a temperature of 200°C. The collision-induced dissociation studies (precursor ion scan or product ion scan) were performed using nitrogen gas at collision energy of 30 V and the collision gas thickness of 4 ϫ 10 14 molecules/cm 2 . The data were analyzed by Sciex MultiView 1.4 software. Quantitation of metabolites was carried out by measuring radioactivity in the individually separated peaks in the radiochromatogram using WinFlow software (IN/US). The post-column elute of rat and dog plasma and dog urine was generated by collecting fractions (FC 204 Fraction Collector; Gilson, Middletown, WI) at 0.5-min intervals. Each fraction was mixed with scintillation cocktail (7 ml) and the radioactivity was determined by counting the fractions in a liquid scintillation counter. The counting efficiency was determined by external standardization. The counts (dpm) were plotted against time of fraction collection to obtain the plasma profile. The percentage of radioactivity for each peak was determined by dividing the number of counts in each peak by the total number of counts.
Enzymatic Hydrolysis. Pooled rat and dog bile samples (0.5 ml each) were adjusted to pH 5 with sodium acetate buffer (0.1 M) and treated with 10,000 units of ␤-glucuronidase from H. pomatia (Prakash and Soliman, 1997) . The mixture was incubated in a shaking water bath at 37°C for 12 h. Control assays were run simultaneously under the same conditions without ␤-glucuronidase to estimate the stability of the glucuronide under such conditions. Incubations were quenched with acetonitrile (1:10) and centrifuged, and the supernatant was evaporated to dryness in a Turbo-Vap under nitrogen. The residue was reconstituted in 300 l of acetonitrile and water mixture (1:3), and a 25-l aliquot was injected onto the column for the identification of the glucuronide.
Microsomal Incubation of Metabolite M2 with Rat Liver Microsomes. Synthetic standard of the amide M2 (10 M) was incubated with rat and dog liver microsomes (protein concentration 1.0 mg/ml), MgCl 2 (3.3 mM), and NADPH (3.0 mM) in a total volume of 1.0 ml of potassium phosphate (0.1 M, pH 7.4). Incubations were started by addition of NADPH and shaken in a water bath set at 37°C for 30 min. At this time, the incubations were quenched with acetonitrile (5 ml) and centrifuged, and the supernatant was evaporated to dryness in a Turbo-Vap under nitrogen. The residue was reconstituted in 150 l of acetonitrile and water mixture (1:3), and a 25-l aliquot was injected onto the column for the identification of the oxidation products.
Metabolic Profiling of Human Plasma and Urine. Plasma and urine obtained from healthy human volunteers dosed with 1000 mg of CP-544439 in the clinical pharmacology dose escalation study of CP-544439 were profiled to assess the circulating and urinary metabolites in humans. Aliquots (100 l) of human plasma collected at 0.5, 1.0, 2.0, 4.0, 6.0, 12.0, and 16.0 h were pooled per subject. Human urine samples collected from 0 to 6, 6 to 12, and 12 to 24 h postdose/subject were pooled (1 ml/sampling time) into a single 0 to 24 h sample for analysis. The pooled plasma and urine samples (1 ml) were treated with acetonitrile (5 ml), and the precipitated proteins were separated by centrifugation for 10 min at 2500 rpm. The supernatant was evaporated to dryness, and the residue was reconstituted with 30% acetonitrile (100 l) and vortexed. A 25-l aliquot of the reconstituted mixture was then profiled by HPLC. The separation was performed as described above except that an Eclipse-XDB column (2.1 ϫ 150 mm, 5 m) was used in the separation of metabolites. In the absence of the radiolabel, the effluent was directed into an UV detector (Hewlett Packard, Palo Alto, CA) that was set at a wavelength of 254 nm. The UV was recorded in real time by the mass spectrometer data system that provided simultaneous detection of UV and total ion chromatogram. No attempt was made to quantify the metabolites in the total ion chromatogram or in the UV chromatogram.
Plasma Protein Binding. The plasma protein binding experiment was conducted by equilibrium dialysis using Spectropor Equilibrium Dialysis System as described previously (Allan et al., 2006) . Fresh plasma was fortified with a methanol standard solution of [
14 C]CP-544439 (specific activity 64.98 mCi/mmol; radiochemical purity Ͼ99%) to yield a final concentration of 0.5, 1.0, and 2.5 g/ml. For determination of CP-544439 binding to human serum albumin or ␣1-acid glycoprotein, fresh stock solution of human serum albumin (45 mg/ml) and ␣1-acid glycoprotein (0.75 mg/ml) in phosphate buffer (pH 7.4) was fortified with a methanol standard solution of [
14 C]CP-544439 to yield a final concentration of 1.0 g/ml. The 1.0-ml triplicate aliquots of fortified stock plasma, HSA, and AAG were dialyzed against 1.0-ml Dulbecco's phosphate-buffered saline (pH 7.4). The assembled dialysis cells were immersed in a water bath at 37°C and rotated at 20 rpm for ϳ16 h. The total volumes of plasma and buffer samples were removed from the dialysis chambers with blunt needle syringes, and the corresponding volumes were measured to account for the volume shift during dialysis.
The plasma and buffer concentrations of CP-544439 were determined by liquid scintillation counting. A 100-ml aliquot of plasma and the buffer containing CP-544439 were mixed with scintillation cocktail (6 ml) and quantified in a Wallac liquid scintillation counter for 5 min. The counting efficiency was determined by external standardization. The unbound plasma free fraction was calculated by using the formulas
where f u is the fraction unbound, f b is the fraction bound, C Pe is the concentration of CP-544439 in plasma at equilibrium, C Be is the concentration of CP-544439 in buffer at equilibrium, V Pe is the plasma volume at equilibrium, and V Pi is the plasma volume at initial time point.
Plasma Stability. CP-544439 was dissolved in methanol to provide a concentration of 0.1 mg/ml. To each 6-ml aliquot of rat, dog, and human plasma, 60 l of the 0.1 mg/ml solution of the CP-544439 were added to produce a final concentration in the incubation of 1.0 g/ml. The fortified plasma was incubated in a water bath for 3 h at 37°C. A 500-l aliquot was taken from each incubation up to 180 min and added to a test tube containing methyl-tert-butyl ether (3 ml). The mixture was vortexed for 1 min and then centrifuged at 3000 rpm. The supernatant (organic layer) was dried in a turbo evaporator under nitrogen, the residue was reconstituted in a mixture of acetonitrile and water (30:70), and the aliquot was analyzed by LC/MS/MS as described above.
WBAL Study. Tissue distribution of [ 14 C]CP-544439 was investigated in six female and six male Long-Evans rats (Charles River Laboratories, Raleigh, NC) following oral administration. [
14 C]CP-544439 was dissolved in 0.1% methyl cellulose/PEG 400 (1:1) mixture at concentration of 44.5 mg/ml and 49 Ci/ml. Specific activity of this dosing formulation was 0.46 mCi/mmol (1.1 Ci/mg). Delivery volumes were approximately 1 ml in order for each rat to receive 275 mg/kg and 302 Ci/kg [ 14 C]CP-544439. [ 14 C]CP-544439 was orally administered to all rats. One rat of each gender was euthanized by CO 2 asphyxiation at 1, 3, 6, 18, 36, and 168 h postdose. Immediately following euthanasia, each rat was prepared for WBAL by immersion into a freezing chamber (Ϫ75°C) containing dry ice and hexanes for 10 min.
The whole-body cryosectioning technique was used to acquire whole-body cryosections for autoradioluminography. Quantification of autoradioluminographic whole-body cryosection images as described by Potchoiba and coworkers was used to determine the radioactive concentrations of [ 14 C]CP-544439 in individual tissues, tissue substructures, and gastrointestinal (GIT) contents (Potchoiba et al., 1995 (Potchoiba et al., , 1998 . The lower limit of quantitation for the WBAL assay was 3.3 nCi/g, whereas the upper limit of quantitation was 21,475 nCi/g. Tissue concentrations of radioactivity (nCi/g) were converted to g equivalents/g (g eq/g) by using the specific activity of the [ 14 C]CP-544439 dose formulation. The pharmacokinetic parameters were calculated from mean tissue concentrations of radioactivity using WinNonLin version 2.1 (Pharsight) as described above.
Identification of Uridine Glucuronyltransferase Isoform Responsible for the Glucuronidation of CP-544439.
Microsomes prepared from baculovirus-infected insect cells that expressed the human UGTs 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, and 2B7 (Supersomes), as well as a control preparation, were obtained from BD Biosciences (Billerica, MA). The glucuronidation activity of Supersomes from each UGT was substantiated by the supplier for the following substrates: estradiol (UGT 1A1 and 1A3), trifluoperazine (UGT 1A4), and 7-hydroxy-4-trifluoromethylcoumarin (UGT 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, and 2B7).
Incubation Procedure. The typical incubation mixture (250 l) contained Supersomes (1.0 mg/ml), MgCl 2 (10 mM), CP-544439 (20 M), and alamethicin (25 g/mg protein) in phosphate buffer (100 mM, pH 7.4). The Supersomes were preincubated at 37°C for 5 min, and the reaction was started by addition of UDPGA (5 mM). After 60 min of incubation at 37°C, the reaction was stopped by addition of 150 l of acetonitrile containing 50 M internal standard. After centrifugation at 3000 rpm, 100 l of supernatant was transferred to a 1.5-ml marsh tube and diluted with 50 l of acetonitrile and water (70:30). Control incubations without microsomes or without cosubstrates were performed in parallel. All samples were analyzed by HPLC-MS system composed of a PE-Sciex 4000 mass spectrometer fitted with a turbo ion spray, a Shimadzu system controller and pumps SCL-10AVP (Shimadzu Scientific Instruments, Columbia, MD), and a LEAP autosampler (CTC Analytics, LEAP Technologies Inc.). Samples (20 l) were injected onto a Phenomenex Synergi Hydro-RP column (30 ϫ 4.6 mm, 4 m; Phenomenex) pre-equilibrated with 0.1% formic acid solution in water, pH 3 (solvent A), and acetonitrile containing 0.1% formic acid (solvent B) at 90:10. The separation of the analytes was accomplished by using a gradient that comprised solvent A at 90% up to 0.3 min that was changed to solvent A at 10% from 0.3 to 0.5 min. Solvent A was then maintained at 10% from 0.5 to 2.30 min and changed to 90% in the next 0.2 min. It was then allowed to equilibrate for 0.5 min between sample injections. The flow rate was maintained at 300 l/min. Detection was accomplished in the positive ion mode on a Sciex 4000, monitoring the metabolite at m/z 587 to 411 and the internal standard at m/z 272.5 to 135.2, respectively. The tune file settings on the mass spectrometer were as follows: source temperature 400°C, declustering potential 41, and collision energy 15 (for the conjugate) and 61 (for the internal standard). The retention time for M1 and the internal standard were 1.3 and 1.4 min, respectively. The peak areas of the conjugate and the internal standard were processed by Sciex Software Analyst 1.4. Since the synthetic standard of the glucuronide conjugate was not available, the ratio of peak area responses of the conjugate relative to internal standard was used to determine the abundance of the conjugate formed by each isoform.
Results
Pharmacokinetics. All studies were conducted using doses that mimicked the tolerated intermediate doses used in toxicology studies. Hence, the absorption, distribution, metabolism, and excretion study in the rat was conducted at 250 mg/kg dose, whereas the study in the dog was conducted at 100 mg/kg dose.
Rat. The mean plasma concentration-versus-time profile for total radioactivity (g-equiv. unchanged CP-544439/ml) and unchanged CP-544439 (g/ml) following single oral administration of [ 14 C]CP-544439 to rat and dog is shown in Fig. 1 . The pharmacokinetic parameters are depicted in Table 1 . After an oral dose of 250 mg/kg [ 14 C]CP-544439 to SD rats, the mean C max of total circulating radioactivity and unchanged CP-544439 was 24.0 g-equiv. of CP-544439/ml and 12.7 g/ml, respectively, and the mean T max was 8.0 and 2.2 h, respectively (Table 1) . The mean AUC 0-ϱ of total radioactivity and unchanged CP-544439 was 635 g-equiv. of CP-544439 h/ml and 102 g ⅐ hr/ml. The mean terminal elimination half-life of total circulating radioactivity and unchanged CP-544439 was 13 and 3.8 h, respectively. Dog. After oral administration of 100 mg/kg [ 14 C]CP-544439 to Beagle dogs, the mean C max of total circulating radioactivity and unchanged CP-544439 was 30.2 g-equiv. of CP-544439/ml and 8.1 g/ml, respectively, and the mean T max was 1.25 and 0.75 h, respec- (Table 1) . The mean AUC 0-ϱ of total radioactivity and unchanged CP-544439 was 491 g-equiv. of CP-544439-h/ml and 32.1 g ⅐ hr/ml. The mean terminal elimination half-life of total circulating radioactivity and the unchanged CP-544439 was 40 and 3.4 h, respectively.
Excretion. Rats. The recovery of the radiolabeled material was essentially complete after oral administration of a single 250 mg/kg dose of [ 14 C]CP-544439 to SD rats. Approximately 63% of the dose was excreted in the feces, whereas 37% of the dose was excreted in the urine after 168 h, resulting in an overall recovery of 100% (Table  2 ). There were no gender differences in the excretion pattern of rats (data not shown). Most of the radioactivity was recovered in the initial 48 h in all rats.
Dogs. The feces was the primary route of excretion in Beagle dogs after a single oral administration of [ 14 C]CP-544439 at a dose of 100 mg/kg. Table 2 shows the percentage of radioactivity excreted in the urine and feces over 168 h postdose. A total 8.2 and 92.8% of the administered dose was excreted in the urine and the feces of the male and female dogs over 168 h, respectively, resulting in a total recovery of approximately 100% ( Table 2) . As in rats, most of the dose was recovered in the first 48 h after dosing of the radiolabeled compound. No gender differences were observed in the excretion pattern of the compound in dogs as well.
Distribution. Plasma protein binding. CP-544439 is a weakly acidic compound with a pK a of 8.7 and is hydrophilic with experimental log P of 1.51. Plasma protein binding for CP-544439 in rat, dog, and human plasma was determined by equilibrium dialysis method at concentrations of 500, 1000, and 2500 ng/ml. CP-544439 exhibited moderate plasma protein binding at values ranging from 88, 90, and 89% at 1 g/ml in rat, dog, and human. There was no change in the free fraction of CP-544439 at the concentrations of 0.5 and 2.5 g/ml, suggesting that the percentage of CP-544439 bound to plasma proteins was independent of its plasma concentrations in all species.
The extent of protein binding of CP-544439 to HSA and ␣-1-glycoprotein was also determined to assess the specificity of the compound toward the two common proteins found in plasma. The percentage of unbound CP-544439 was 16 and 93% in HSA and AAG solutions, respectively. This suggested that HSA was the major binding protein for CP-544439 in human plasma.
Incubation of CP-544439 with rat, dog, and human plasma was also conducted to assess the hydrolysis of the compound by plasma esterases. This resulted in a half-life of ϳ52 min when CP-544439 was incubated with rat plasma. However, no turnover was observed when the compound was incubated with dog and human plasma, resulting in a half-life of Ͼ300 min in both species.
Tissue distribution. Tissue distribution of CP-544439 was investigated by WBAL following an oral 275 mg/kg dose of [
14 C]CP-544439. [
14 C]CP-544439 radioequivalents were absorbed and distributed into most tissues of Long-Evans female and male rats after a single oral bolus dose. Table 3 depicts [ 14 C]CP-544439 radioequivalents expressed as g eq/g in tissues from female and male rats. The absorption and distribution was rapid since most tissues showed radioactivity levels by 1 h after dosing in both genders. [
14 C]CP-544439 radioequivalents achieved C max at 6 h in the female rat and at 18 h in the male rat in most tissues with few exceptions (Table 4) . One exception was the periodontal ligament, which achieved C max at 168 h in both genders. All but 6 tissues in the male and female rats were devoid of radioactivity by 36 h postdose, suggesting that [
14 C]CP-544439 radioequivalents were eliminated rapidly from the body. The liver, lung, periodontal ligament, myocardial blood, kidney, and exorbital lacrimal gland sustained radioactivity equivalents for at least 36 h. By 168 h postdose, the periodontal ligament was the only tissue containing [
14 C]CP-544439 radioequivalents in both rat genders. The apparent t 1/2 for most female and male tissues could not be determined since a definitive elimination phase was not discernible. For the female rat, only four tissues (i.e., liver, myocardial blood, exorbital lacrimal gland, and the kidney) had measurable t 1/2 that ranged from 8 to 22 h. The apparent t 1/2 of [ 14 C]CP-544439 radioactivity in the whole-body was approximately 6 h for both rat genders.
The highest concentrations of [ 14 C]CP-544439 radioequivalents were found in the GIT tract in both genders as was expected. Drugassociated radioactivity present in GIT contents plausibly represented unabsorbed [
14 C]CP-544439 as well as [ 14 C]CP-544439 related material that was excreted via the bile or intestinal secretion. Interestingly, the periodontal ligament showed high concentrations of radioequivalents even at 168 h postdose, resulting in exposures of 8765 and 9921 g eq ⅐ h/g in the female and male rat (Table 4) . Assessment of the tissues in the central nervous system indicated that [
14 C]CP-544439 radioequivalents primarily distributed into the cerebellum and cerebrum. All other central nervous system tissues did not show any appreciable levels of radioequivalents except at 1 h postdose (Table  3) . Drug equivalents did not distribute into ocular tissues that lacked melanin since radiolabel was only detected in the uvea, a melanincontaining tissue, up to 6 to 18 h postdose. The exposure of [ 14 C]CP-544439 in the uvea of the female and male rat was 34 and 147 g eq ⅐ hr/g, respectively (Table 4 ). The reason for the 4-fold higher exposure to radioactivity in the male rat is not known.
Some other gender differences were also observed in the distribution of [
14 C]CP-544439. The male exorbital lacrimal gland depicted a 24-fold greater exposure to the radiolabel than the female rat, whereas the male liver showed 1.8-fold greater radioequivalents. The wholebody exposure to [
14 C]CP-544439 radioequivalents also was approximately 2-fold higher in the male rat than in the female.
Metabolism of CP-544439. The metabolism of CP-544439 in rat and dog was assessed by profiling urine, bile, plasma, and the fecal 
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homogenate from the two species. As a first step, the biological matrices from the rat and dog were pooled to account for Ͼ95% of the radioactivity.
Rat. Representative HPLC-radiochromatograms of the extracted urinary (urine pooled from 0 -72 h) and fecal (pooled from 0 -48 h) samples from rat are shown in Fig. 2 . The mean percentage of each metabolite excreted in rat urine and feces is shown in Table 5 . The urinary profile showed 6 peaks including the unchanged CP-544439 ( Fig. 2A) . Only 8.3% of the dose was excreted as unchanged CP-544439 (ret. time 18.33 min) in the rat urine. Major peaks eluting at 21.3, 24.3, 16.7, and 14 .3 min represented metabolites M2, M3, M5, and M6 and accounted for 6.6, 5.3, 6.0, and 4.3% of the dose, respectively, whereas peak eluting at 10.1 min represented metabolite M1 and constituted a mean 1.2% of the dose. Metabolite M4 was detected as a minor metabolite in the radiochromatogram and almost coeluted with M2. Hence, its relative abundance in the urinary profile could not be determined. The peak eluting at 1.5 min was not identified and represented 2.2% of the dose. The HPLC-radiochromatogram of the fecal extract showed 5 peaks including unchanged CP-544439 (Fig. 2B) . The major radioactive peak was unchanged CP-544439 and accounted for 29% of the dose (Table 5 ). The peaks eluting at 21.3 and 24.3 min represented M2 and M3 and accounted for 19 and 3.9% of the dose, respectively. Other peaks, M6 and M7 eluting at 16.7 and 7.4 min, represented 4.6 and 2.2% of the dose, respectively.
The radiochromatogram of the rat bile is shown in Fig. 3A . Since bile was collected for 24 h only, the abundance of metabolites was expressed as a percentage of radioactivity. The major peak was M1 and eluted at ϳ10 min, representing 75.8% of the total radioactivity excreted in bile in 24 h. Metabolite M3 eluted at 26.4 min and coeluted with M8, a new peak that was not observed in the urine or feces. The metabolites together represented 6.1% of the radioactivity. Metabolite M2 eluted at 23.2 min and accounted for 2.6% of the radioactivity. The unknown peaks eluting at 1.4 to 6.05 min accounted for 4.7% of the radioactivity.
Approximately 89% of the circulating radioactivity in the plasma pooled from 0 to 72 h postdose could be identified. The rest could not be distinguished from the background. Three metabolites and unchanged CP-544439 were present in the plasma (Fig. 3B) . Metabolites M1, M2, M3 and the unchanged CP-544439 accounted for most of the radioactivity and constituted 2.9, 23, 32.8, and 10.7% of the circulating radioactivity, respectively (Fig. 3B) .
Dog. The analysis of pooled urine sample (0 -72 h) showed 7 peaks including the unchanged CP-544439 (Fig. 4A ) in HPLC-radiochromatogram. Unchanged CP-544439 represented only 1.5% of the dose excreted in the urine (Table 5 ). Metabolite M1, eluting at 11 min, was the major urinary metabolite, representing 3.2% of the dose. Other peaks representing metabolites M2, M3 and M8, M5, M6, and M7 were also detected in the urine, but each metabolite represented Ͻ1% of the radioactive dose. All metabolites together accounted for 2.4% of the excreted dose. The HPLC-radiochromatogram of the fecal extract pooled from 0 -72 h showed only one peak, eluting at ϳ20 min, and accounted for 100% of the dose excreted in the feces ( Fig.  4B ; Table 5 ). Similarly, profiling of the bile sample collected from 0 -8 h from bile-cannulated dog showed only one peak, eluting at 11 min, and accounted for 100% of the radioactivity excreted in the bile (Fig. 5A) . The retention times of the peaks in the fecal extract were similar to that of the unchanged CP-544439, and the peak at 11 min in the bile represented metabolite M1.
Approximately 88% of the circulating radioactivity in the plasma pooled at 0 -72 h postdose could be identified (Fig. 5B) . The rest could not be distinguished from the background. Five major peaks and three minor metabolites were observed in the radiochromatogram of dog plasma that was constructed after collecting fractions and counting the radioactivity in each fraction. The retention times at 11, 19, 21.3, and 24.7 matched those of metabolites M1, CP-544439, M2, and a mixture of M3 and M8 and accounted for 24, 31, 4.0, and 8.7% of the total circulating radioactivity. In the mixture of M3 and M8 eluting at 24.7 min, M8 was the major constituent, whereas M3 represented a minor metabolite. However, an exact abundance could not be determined from the data. A new peak eluting at 8.3 min (M9) was also observed in the plasma profile and accounted for 7.0% of the total circulating radioactivity (Fig. 5B) .
Metabolic Profiles of CP-544439 in Human Plasma and Urine. The plasma and urine obtained from healthy human volunteers dosed with CP-544439 at 1000 mg once per day in a clinical pharmacology dose escalation study were analyzed to assess the metabolic profile of CP-544439 in humans in vivo. The high dose was selected for metabolite profiling to ensure that all metabolites were detected in the human plasma. Since the CP-544439 dosed to healthy human volunteers was unlabeled, only a qualitative assessment of metabolites was possible. However, presence of the UV detector in line with the mass at ASPET Journals on July 7, 2017 dmd.aspetjournals.org spectrometer gave an idea of major and minor metabolites that were circulating or excreted in humans. The UV chromatogram of plasma and urine showed 4 and 6 peaks, respectively, the retention times of which were similar to M1 at 11 min, CP-544439 at 19 min, M2 at 22 min, and M3 at 24.7 min in the rat and dog (Fig. 6) . The UV chromatogram of human urine showed 2 additional peaks eluting at 18 and 19 min, respectively, which were similar to metabolites M5 and M6 observed in rat urine (Fig. 6B) . Metabolite Identification. The structures of metabolites were elucidated by ion spray LC/MS/MS using a combination of full precursor ion and neutral loss scanning techniques. All metabolites were further characterized using the product ion scans of the identified masses. CP-544439 gave a good signal at m/z 409 in a full scan in the negative ion mode. The parameters of the mass spectrometer were thus optimized in this mode for the product ions of m/z 409.
The proposed characteristic molecular ion [M-H]
Ϫ and product ions of CP-544439 and its metabolites are depicted in Scheme 2. The product ion mass spectrum of m/z 409 gave one major characteristic fragment ion at m/z 266. This ion represented the sulfonamide moiety of the molecule. Another minor fragment ion was observed at m/z 251, which suggested a loss of ammonia from m/z 266, as shown in Scheme 2. The precursor ion scan of m/z 266 was therefore used to identify metabolites that had modifications on the tetrahydropyranyl-hydroxamate moiety. Other LC/ MS/MS experiments conducted were the precursor ion scan of m/z 282, which corresponded to the oxidized sulfonamide group (m/z 266 ϩ 16). No attempt was made to isolate the metabolites to obtain conclusive NMR spectra; however, the structures of metabolites were confirmed by comparison of their retention time, and mass spectra with the synthetic standards of the metabolites were available. The structures/proposed structures of metabolites of CP-544439 are shown in Scheme 3. (Wang et al., 2003) . The ions at m/z 266 and 251 were similar to those observed in the parent and suggested that the sulfonamide moiety was intact. The retention time and the product ion mass spectrum of the metabolite were similar to the mass spectrum of the authentic standard of the amide (data not shown), further confirming that M2 was an amide analog of CP-544439.
Metabolite M3 gave a strong signal at m/z 394 in the precursor ion scan of m/z 266 The product ion mass spectrum of m/z 394 gave fragment ions at m/z 350, 266, and 251 in the negative ion mode (Scheme 2). The fragment ion at m/z 350 indicated a loss of the carboxy group (44 amu). The ions at m/z 266 and 251 were similar to those observed in the mass spectrum of M2 and CP-544439 and suggested that the sulfonamide moiety was intact as seen in M2.
Comparison of the retention time and product ion mass spectrum of the metabolite with that of authentic standard of the carboxylic acid analog of CP-544439 indicated that the M3 was a carboxylic acid.
Metabolite M4, which coeluted with M2 in the chromatogram of the rat urine, gave a signal at m/z 407 in the precursor ion scan of m/z 266, respectively, suggesting an addition of 14 amu to m/z 393. The product ion mass spectra of m/z 407 gave fragment ions at m/z 335, 266, and 251 in the negative ion mode (Scheme 2). The presence of ions at m/z 266 and 251 suggested that the sulfonamide moiety was intact as observed previously and indicated that the tetrahydropyranyl moiety was modified, possibly to a tetrahydropyrone. The ion at m/z 335 indicated a loss of 72 amu and suggested a cleavage of the tetrahydropyrone moiety. Based on this data, the metabolites were proposed to be lactone of the amide.
Metabolites M5 and M6 gave strong signals at m/z 409, a ion similar to CP-544439, in the precursor ion scan of m/z 266. A molecular ion similar to CP-544439, but a different retention time and modification of the sulfonamide-containing moiety, suggested that 
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this metabolite resulted from the oxidation of the amide (M2). The product ion mass spectra of these two metabolites were similar and showed major fragment ions at m/z 335 and 266 (Scheme 2). The presence of an ion at m/z 266 confirmed that the sulfonamide moiety was intact. The ion at m/z 335 suggested a loss of 74 amu that probably resulted from the cleavage of the tetrahydropyrone moiety as observed in the fragmentation of M4. Based on this data, M5 and M6 were proposed as hydroxylated metabolites of the amide, M2. This was confirmed by incubation of synthetic M2 with rat liver microsomes in the presence of NADPH (data not shown). The detection of these two metabolites in the incubation mixture not only confirmed that M5 and M6 were oxidized metabolites of M2 but also showed that the amide was a substrate of P450. The metabolites were absent in the control (without NADPH) incubations. No attempt was made to further characterize the P450 involved in the oxidation of M2. Metabolite M7 also showed a molecular ion at m/z 409 in the precursor ion scan of m/z 282. The absence of the signal in the precursor ion scan of m/z 266 indicated that the sulfonamide ring in this metabolite was modified. A molecular ion similar to CP-544439, but a different retention time and modification of the sulfonamidecontaining moiety, suggested that this metabolite also resulted from the oxidation of the amide (M2). The product ion mass spectrum of M7 at m/z 409 resulted in the fragment ions at m/z 345, 282, and 267 (Scheme 2). All fragment ions observed in the mass spectrum of M7 were consistent with an addition of 16 amu to the fragment ions observed in the mass spectrum of M2. This data suggested that the amide underwent hydroxylation on one of the aromatic rings. However, the exact position of the hydroxyl group could not be ascertained from this data.
Metabolite M8 coeluted with the acid M3 and gave a strong signal at m/z 266 in the total ion scan. This indicated that the metabolite had lost its tetrahydropyranyl moiety and was a cleaved product of N.D., not detected. a Metabolite M4 coeluted with M2 but was a minor component of the peak (Fig. 2) . b Metabolite M8 coeluted with M3. The amount of M8 could not be assessed (Fig. 4) . (Fig. 7A) . The fragment ion at m/z 202 resulted from the rearrangement product following a loss of the SO 2 moiety from M8 as shown in Fig. 7A . A loss of 64 amu was also observed in the fragmentation of the amide metabolite M2 (described above) and was characteristic of the presence of the sulfonamide group in the molecule. The ion at m/z 107 probably resulted from further loss of the fluorophenyl moiety m/z 202. The mass spectral data suggested that the M8 was a sulfonamide metabolite of CP-544439. The retention time and the product ion mass spectrum of M8 was similar to that of the authentic sulfonamide standard and hence further confirmed its identity. Metabolite M9 gave a signal at m/z 267 in the total ion scan. The product ion mass spectrum of m/z 267 gave major fragment ions at m/z 203, 172, and 108 (Fig. 7B) . The ion at m/z 172 indicated a loss of the fluorophenyl moiety from the molecule. The minor fragment ion at m/z 203 resulted from a loss of SO 2 moiety as was observed in M8 and M2, and the fragment ion at m/z 108 was a result of further cleavage and loss of the fluorophenyl moiety from m/z 203. Based on this data, the metabolite was proposed to be a sulfonic acid. No attempt was made to confirm the structure of the metabolite.
In Vitro Studies on Glucuronidation of CP-544439. Preliminary experiments were conducted to identify the primary UDP glucuronyltransferase isoforms responsible for the glucuronidation of CP-544439 using 12 heterologously expressed human UGTs (Supersomes). Figure 8 shows the amount of glucuronide conjugate formed following incubation of CP-544439 by various isoforms of UGT. All UGTs glucuronidated CP-544439; however, UGTs 1A3, 1A1, and 1A9 were the primary isoforms that catalyzed the formation of M1. No attempt was made to determine the K m and V max for this glucuronidation reaction.
Discussion
This study described the disposition and metabolism of [ 14 C]CP-544439 in rat and dog, the animal species used in safety toxicology studies, after oral administration. In addition, the circulating and urinary metabolic profile of CP-544439 in humans was assessed using the plasma and urine samples from the dose escalation study in healthy human volunteers to ensure that the selected animal species were exposed to all major metabolites formed in humans.
The radioactive dose was quantitatively recovered from urine and feces of both the rat and dog over a period of 168 h. The recovery was essentially complete within 48 h, suggesting rapid excretion of CP-544439 and its metabolites. Most of the radioactivity was excreted in the feces of both species and probably consisted of unabsorbed dose and the dose that was excreted via the bile. No gender-related differences were observed in the two species. A proper assessment of total absorption could not be made in this study since bile was collected for a limited time for sake of profiling biliary metabolites.
Pharmacokinetic analysis of [ 14 C]CP-544439 and unchanged CP-544439 indicated that the exposure (AUC 0-ϱ ) of unchanged CP-544439 in rat and dog was 16 and 6.5% of the total radioequivalents, respectively, indicating that majority of the circulating radioactivity comprised of metabolites. In rat, the T max of total radioactivity SCHEME 2. Major collision-induced dissociation product ions of CP-544439 and its metabolites.
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at ASPET Journals on July 7, 2017 dmd.aspetjournals.org Downloaded from (8 h) was longer than the T max of unchanged CP-544439 (2.2 h), suggesting that, although the absorption of [ 14 C]CP-544439 was rapid, one or more metabolites of CP-544439 peaked at a later time. In contrast, the T max of total radiolabel and unchanged CP-544439 in the dog was 1.25 and 0.75 h, respectively, which suggested that one or more metabolites peaked at the same time as unchanged CP-544439. Only 26% of C max constituted unchanged CP-544439 in dogs, suggesting that the metabolites accounted for most of the at ASPET Journals on July 7, 2017 dmd.aspetjournals.org Downloaded from radioactivity in the peak concentrations. The terminal elimination half-life of the total radioactivity was longer than that of unchanged CP-544439 in both species, signifying that some circulating metabolites had a longer half-life than CP-544439.
[ 14 C]CP-544439 distributed into most tissues of female and male Long-Evans rats except the central nervous system. Exposure to [ 14 C]CP-544439 in the cerebellum and cerebrum were similar to that of arterial blood. Poor distribution in the central nervous system illustrated minimal permeability of CP-544439 and its metabolites across the blood brain barrier. The uvea, a melanin-containing tissue in the eye, also had minimal exposure to [
14 C]CP-544439. Most radioactivity was eliminated from the uveal tract, illustrating that this compound did not have a high affinity for melanin. The highest concentrations of radioequivalents were found in the contents of the GIT and probably resulted from unabsorbed material following oral administration or from biliary elimination of radioequivalents. The periodontal ligament showed maximum exposure to CP-544439 radioequivalents. The periodontal ligament is a group of specialized connective tissue fibers that essentially attaches a tooth to the alveolar bone within which it sits. These fibers are composed primarily of type I collagen and are highly vascularized. The persistent radioactivity associated with the periodontal ligament was probably due to the intense vascularization and collagen content of this structure. The lack of detectable radiolabel in other target tissues of interest (articulations of the skeletal system and macular region of the retina) was not surprising since the rats used in this study were not affected with the neogenic vascularization associated with rheumatoid arthritis and age-related exudative macular degeneration. However, the marrow of the long and compact bone, another target tissue of interest, demonstrated radioactivity up to 18 h postdose.
CP-544439 was extensively metabolized in both species. Only 8.4 and 1.5% of the total dose constituted unchanged CP-544439 in the rat and dog urine, respectively, and there was no unchanged CP-544439 in the bile of the two species. Reduction of CP-544439 to M2 (Scheme 3) was the major route of metabolism in rats. It was a major component of the rat excreta (25.6% of the total dose) and accounted for 23% of the total circulating radioactivity. Furthermore, some secondary oxidative metabolites, M5, M6, and M7 of M2, were detected in the rat, suggesting that the amide was a substrate for cytochrome P450. Reduction of hydroxamates to amide has been previously reported and is catalyzed by aldehyde oxidase, a member of molybdenum cofactorcontaining enzymes (Sugihara et al., 1983a,b; Sugihara and Tatsumi, 1986) . Earlier work by Obach has demonstrated that aldehyde oxidase catalyzes conversion of CP-544439 to M2 (Obach, 2004) . In contrast to rats, reduction of CP-544439 was a relatively minor pathway in dogs. This difference between the rat and dog was most likely related to the low activity of dog liver aldehyde oxidase (Beedham et al., 1987; Acheampong et al., 1996; Kitamura et al., 1999) .
Hydrolysis of CP-544439 to M3 (Scheme 3) was the second major pathway of metabolism of CP-544439 in the rat. It accounted for 9.2% of the total dose in the excreta and represented ϳ33% of the total circulating radioactivity. No downstream metabolites of M3 such as the acylglucuronide or any oxidative metabolites were detected in the urine or plasma. Unlike in rats, M3 was also a minor metabolite in dogs. Although the exact percent of circulating M3 could not be determined due to its coelution with M8, the comparison of the peak areas of M3 in the extracted ion chromatogram of pooled plasma indicated that it was a minor circulating metabolite. The above result correlated with the in vitro studies with CP-544439, which showed instability of the compound in rat plasma but not in the dogs or humans. This was also consistent with reports that demonstrate that rat plasma has greater hydrolytic capability than other species (Honohan et al., 1980; Allan et al., 2006) . Although it is possible that M3 was a result of the amidase catalyzed hydrolysis of the amide M2, incubation of synthetic M2 with rat plasma did not yield the corresponding M3. Furthermore, M2 was stable to chemical hydrolysis in buffer at acidic and basic pH, ruling out the possibility of an artifact of a chemical hydrolysis in the mobile phase. This was consistent with earlier reports that have demonstrated the hydrolytic cleavage of hydroxamates to the corresponding carboxylic acid (Kobashi et al., 1973; Conejo-Garcia and Schofield, 2005) CP-544439 was also converted to the glucuronide M1 in the rat and dog. It was the primary circulating metabolite in dog plasma (24% of the total radioactivity) and was the only metabolite detected in dog bile. In contrast, the glucuronide conjugate M1 was only observed in rat bile and constituted 76% of biliary radioactivity. In addition, two novel metabolites resulting from cleavage of CP-544439 were also detected in the dogs. The sulfonamide metabolite (M8), which coeluted with M3 and its hydrolytic product, the sulfonic acid metabolite M9, was primarily detected as a circulating metabolite. The mechanism for formation of M8 and M9 is unknown. However, one plausible pathway could involve the Lossen rearrangement. This is a base catalyzed rearrangement of O-acylhydroxamic acids that yield the corresponding isocyanates (Bauer and Exner, 1974) , which could then be converted to carbamates via treatment with appropriate alcohols or to amine via hydrolysis. A similar rearrangement of the conjugated CP-544439 can result in the formation of the isocyanate, which can yield the corresponding M8 via hydrolysis and subsequent decarboxylation (Scheme 4). The sulfonic acid M9 is possibly a hydrolysis product of M8. It should be noted that such a rearrangement is unprecedented in biological systems to our knowledge. Also, the formation of O-acyl derivatives of hydroxamic acids such as the sulfate conjugate or the acetyl conjugates was not observed in the biological matrices of animal species. Profiling of human plasma and urine revealed that metabolites of CP-544439 observed in the humans were similar to those observed in the rat and dog. Although proper assessment of the amount of each circulating and urinary metabolite could not be made, the glucuronide conjugate was the major circulating and urinary metabolite in humans (based on the UV chromatogram). Preliminary experiments using heterologously expressed UGTs suggested that glucuronidation of CP-544439 was catalyzed predominantly by UGT1A1, UGT1A3, and UGT1A9. Determination of the kinetic parameters of glucuronidation by these three UGT isoforms was not attempted given the lack of the authentic glucuronide conjugate. UGT1A1 is an enzyme that displays significant genetic polymorphism (Fisher et al., 2001) . Although metabolism by UGT1A1 can lead to interindividual variability in exposure of CP-544439, such impact is not anticipated since CP-544439 is metabolized by several pathways in humans. Furthermore, no safety concerns around the N-O glucuronide (M1) are anticipated given that these glucuronides do not undergo acyl migration, unlike the acylglucuronides, and no hydrolytic cleavage of these metabolites was observed.
In summary, CP-544439 is widely distributed to all tissues and is primarily eliminated via the feces. Biotransformation of CP-544439 occurs mainly via glucuronidation, reduction, and hydrolysis of the hydroxamate moiety. All three pathways observed in humans are also prevalent in the rat and dog. Reduction of CP-544439 appears to be the primary route of metabolism in the rat, whereas glucuronidation is the primary route of metabolism of CP-544439 in the dog and humans. Preliminary in vitro phenotyping studies suggest that glucuronide conjugate formation is primarily catalyzed by UGT1A1, UGT1A3, and UGT1A9 in humans.
